Saniona AB
STO:SANION
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| DK |
|
Saniona AB
STO:SANION
|
3.4B SEK |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
399.2B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
202.4B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
188.1B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
121B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
82.1B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
74.2B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
44.2B EUR |
Loading...
|
|
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR |
Loading...
|
Market Distribution
| Min | -2 199.8% |
| 30th Percentile | 26.7% |
| Median | 45.7% |
| 70th Percentile | 65.9% |
| Max | 1 637.7% |
Other Profitability Ratios
Saniona AB
Glance View
Saniona AB engages in the research and development on drugs for diseases of the central nervous system, autoimmune diseases, metabolic diseases, and treatment of pain. The company operates in the area of drugs targeting ion channels to develop therapeutics for pain, central nervous system, and inflammatory or autoimmune diseases. The firm develops a technology platform which enables investigation of all types of ion channel drug targets. Its research is focused on GABAA receptors, nicotinic acetylcholine receptors and potassium channels. The clinical pipeline includes: AN788, a clinical candidate for second line treatment of major depressive disorder (MDD); AN761, to be developed for cognition deficits in schizophrenia and Alzheimer's disease; AN363, a candidate for treatment of pain disorders; and AN346, an anti-inflammatory treatment in inflammatory bowel disease (IBD); as well as several other projects. The firm is engaged in partnerships with Janssen Pharmaceuticals Inc, Pfizer Inc and Atlas Venture Inc.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Saniona AB is 90.1%, which is above its 3-year median of -121.6%.
Over the last 3 years, Saniona AB’s Gross Margin has increased from -1 376.9% to 90.1%. During this period, it reached a low of -1 376.9% on Sep 30, 2022 and a high of 90.1% on Sep 30, 2025.
